🇺🇸 FDA
Pipeline program

SDX-101 (R-Etodolac)

SDX-101-04

Phase 2 small_molecule terminated

Quick answer

SDX-101 (R-Etodolac) for Multiple Myeloma is a Phase 2 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Multiple Myeloma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials